Targeting of CIRP attenuates osteoarthritis progression via suppressing TLR4/NF‑κB/NLRP3 signaling axis
International Journal of Molecular Medicine · 2025
DOI: 10.3892/ijmm.2025.5674 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2025. Verfasst von Weichao Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangd…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Toll-Like Receptor 4, Osteoarthritis, NF-kappa B. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Osteoarthritis (OA) is one of the most common joint diseases worldwide. Recently, cold‑inducible RNA binding protein (CIRP), a novel identified pro‑inflammatory cytokine, was reportedly increased in the synovial fluid of OA patients. However, its function and the underlying mechanism in OA progression remains unclear. Therefore, the current study investigated the role of CIRP in the progression of OA. It was observed that CIRP and matrix metalloproteinases were highly expressed in OA chondrocytes, whereas collagen Ⅱ exhibited low expression levels. Additionally, CIRP was found to be secreted by OA human chondrocytes in the form of exosomes. CIRP treatment influenced inflammatory related signaling pathway, which in turn affected inflammatory response and extracellular matrix (ECM) degradation in human chondrocytes. Additionally, CIRP induced the nuclear translocation of p65 and promoted ECM degradation dependent the Toll‑like receptor 4 (TLR4)/NF‑κB signaling. The present study also reported that CIRP increased the IL‑1β secretion via the NLR family pyrin domain containing 3 (NLRP3) inflammasome. Furthermore, targeting of CIRP by microRNA‑145 or exosome loading with microRNA‑145 attenuated its role in promoting OA both in vitro and in vivo. The findings indicated that CIRP acts as a pro‑inflammatory factor and activates the TLR4/NF‑κB/NLRP3 pathway, which promotes the inflammatory response, ECM degradation and the progression of OA and targeting CIRP could be a novel strategy for OA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong 518035, P.R. China.
- Department of Technical Support, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, Guangxi 530021, P.R. China.
- Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646099, P.R. China.
- Department of Physiology, School of Basic Medical Science, Southwest Medical University, Luzhou, Sichuan 646099, P.R. China.
- Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Zitieren
APA
Sun, W., Liao, Y., Feng, J., Liang, J., He, Q., Cui, Y., Huang, D., Shi, H., You, W., Sun, W., & Yi, Q. (2025). Targeting of CIRP attenuates osteoarthritis progression via suppressing TLR4/NF‑κB/NLRP3 signaling axis. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2025.5674
Vancouver
Sun W, Liao Y, Feng J, Liang J, He Q, Cui Y, et al. Targeting of CIRP attenuates osteoarthritis progression via suppressing TLR4/NF‑κB/NLRP3 signaling axis. International Journal of Molecular Medicine. 2025. doi:10.3892/ijmm.2025.5674
BibTeX
@article{Sun2025,
author = {Sun, Weichao and Liao, Yi and Feng, Jianguo and Liang, Jianhui and He, Qifei and Cui, Yinxing and Huang, Dixi and Shi, Houyin and You, Wei and Sun, Wei and Yi, Qian},
title = {Targeting of CIRP attenuates osteoarthritis progression via suppressing TLR4/NF‑κB/NLRP3 signaling axis},
journal = {International Journal of Molecular Medicine},
year = {2025},
doi = {10.3892/ijmm.2025.5674}
}
EUVIMED